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plained heterogeneity weakens our inference (Table1).
Table 1. Estimate of Risk for Developing VOD
Subgroup
Investigations
Contributing data
OR with 95%
Confidence Interval I2
All trials Ohashi, Ruutu, Essell 92,
and 98, Carerras,
Thompson
0.33 [0.12, 0.90] 67.6%
Clinical trial Ohashi, Ruutu, Essell 98 0.30 [0.03, 2.80] 70.5%
Observational study Thompson, Carerras,
Essell 92
0.36 [0.11, 1.23] 80.4%
Busulfan conditioned
patients
Essell 92, Essell 98,
Ohashi
0.19 [0.06, 0.59] 41%
TBI conditioned patients Ohashi, Ruutu 0.37 [0.03, 4.84] 67%
Seattle criteria Essell 92, Essell 98,
Ruutu, Thompson
0.40 [0.12, 1.37] 76%
modified Seattle criteria Carerras, Ohashi 0.17 [0.04, 0.64] 0%
Allogeneic transplant
recipients
Essell 92, Essell 98,
Ohashi, Ruutu,
Thompson
0.33 [0.11, 0.99] 73.7%
I2 represents the precentage of unexplained heterogeneity.
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A RETROSPECTIVE ANALYSIS OF THE IMPACT OF ERYTHROPOEITIC
GROWTH FACTOR UTILIZATION ON TRANSFUSION REQUIREMENTS IN
PATIENTS WITH AL AMYLOIDOSIS UNDERGOING AUTOLOGOUS SCT
Baribeault, D.M.1, Shah, B.1, Finn, K.T.1, Seldin, D.C.1, Quillen, K.1,
Sanchorawala, V.1 Boston Medical Center, Boston, MA.
Introduction: The beneﬁt of the addition of erythropoietin-
derived growth factors (EPOs) to neutrophil growth factors to
hasten engraftment and decrease transfusion requirements in pa-
tients undergoing hematopoietic stem cell transplantation is un-
certain. We previously reported the equivalence between erythro-
poetin alfa and long-acting darbepoetin alfa in patients with AL
amyloidosis undergoing autologous stem cell transplantation
(ASCT). To further evaluate EPOs in this patient population, we
examined the time to neutrophil engraftment and transfusion re-
quirements in all patients undergoing ASCT for AL amyloidosis
over a 10 year period. Methods: A retrospective review was con-
ducted of all patients undergoing ASCT between July 1994 and
July 2005. Three groups were compared. Group A consisted of
patients treated with darbepoetin alfa at 200 mcg weekly (n  64),
Group B consisted of patients treated with epoetin alfa at either
150 u/kg thrice weekly or 40,000 units weekly (n  151), and
Group C consisted of those patients not treated with EPOs (n 
161). All groups were treated with GCSF to promote neutrophil
engraftment. Primary endpoints evaluated were mean number of
units of PRBCs transfused and time to neutrophil engraftment. A
secondary endpoint was the proportion of patients requiring PRBC
transfusion. Groups were stratiﬁed by intensity of conditioning
regimen as well as for life-threatening bleeding events and re-
analyzed. A nonparametric analysis of variance was conducted
utilizing the Kruskal-Wallis test with plans for a Dunn comparison
of all three groups in the event of a P value  0.05. Results: The
mean number of PRBC units transfused was 3.23, 4.5, and 3.92 for
Groups A, B, and C, respectively; P  .1591. The mean number of
days to engraftment was 9.87, 10.3, and 10.4 for the groups; P 
.0956. When life threatening bleeding events were excluded, there
was still no signiﬁcant difference, P  .12. In the subgroup of
patients receiving the highest dose (200 mg/m2) of melphalan, the
proportion of patients not requiring RBC transfusion was higher in
the group receiving EPOs (38% versus 23%, P  .0512, 2).
Discussion: In this analysis, we were unable to demonstrate a
beneﬁt for EPOs in the entire patient group, which is heteroge-
nous in terms of chemotherapy dosing and bleeding complications.
However, when we examined those patients receiving the highest
dose of chemotherapy, an increase in the percentage of patients not
requiring RBC transfusion support was seen.
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MELPHALAN-INDUCED SEVERE ORAL MUCOSITIS IS PREVENTED BY
ORAL CRYOTHERAPY IN AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANT RECIPIENTS
Rimkus, C.F.1, Waller, P.1, Oliver, D.A.1, Richart, J.M.1,
Pincus, S.M.1 Saint Louis University, St. Louis, MO.
Background: Oral mucositis is an expected complication of high
dose mephalan chemotherapy due to its cytotoxic effects. Severe
mucositis leads to complications of severe pain requiring narcotic
management, difﬁculty or inability to eat and take oral medica-
tions, and prolonged hospital stays. Melphalan has a very short
plasma half-life making it an ideal candidate for cryotherapy inter-
vention.
Objective: Primary objective is to evaluate whether the cryo-
therapy intervention will reduce mucositis in patients receiving
high dose melphalan compared to historical controls. Secondary
objectives included determining the tolerance of the procedure and
comparing the need for intravenous narcotics to historical controls.
Methods:The program assessed a modiﬁed version of cytotherapy
intervention protocols reported previously by two institutions.
Patients and staff were given written and verbal instructions de-
scribing the oral cryotherapy intervention. The procedure in-
cluded holding cold medium (ice, popsicle, cold ﬂuid) in the mouth
beginning 10 minutes before the melphalan infusion and continu-
ing until 1 hour after the infusion was completed. Results: Con-
secutive patients (multiple myeloma 18, NHL 13, other 3) being
conditioned with melphalan were eligible. The cryotherapy inter-
vention was used 04/04&ndash09/05, (n  20). A retrospective
review of previous consecutive transplants provided the melphalan
matched controls (03/02–03/04), n  14. Most (90%) of the
patients were able to complete the entire procedure for oral cryo-
therapy. Two patient (10%) intermittently followed the procedure
because they felt too full from drinking cold ﬂuid. Subsequently,
cold ﬂuid has been eliminated as an option for treatment. Forty-
three percent of historical controls had severe mucositis compared
to none of the patients who received cryotherapy (Table). Addi-
tionally, a dramatic difference in the amount of opiate used was
noted. In the historical control group 47% of patients required IV
PCA (cummulative dose MSO4 937mg and Fentanyl 11,850 mcg)
compared to 10% in the cryotherapy group (cumulative 68 mg
MSO4) (Table 1). Summary: Cryotherapy was well tolerated and
appeared to decrease mucositis in high dose melphalan recipients.
Additionally, there was a decrease in IV pain medication use re-
sulting in less overall morbidity.
Table 1. Mucositis in Melphalan Recipients
Intervention Patients None/Mild Moderate Severe
No cryotherapy 14 6 (43%) 2 (14%) 6 (43%)*
Cryotherapy 20 17 (85%) 3 (15%) 0
*Two intubated for airway protection.
398
PHASE III TRIAL OF VALACYCLOVIR FOR THE PREVENTION OF SHIN-
GLES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Klein, A.K.1, DesJardins, J.1, Koc, Y.2, Miller, K.B.3, Schenkein, D.S.1,
Sprague, K.S.1, Snydman, D.R.1 1. Tufts-New England Medical Cen-
ter, Boston, MA; 2. Hacettepe University, Ankara, Turkey; 3. Beth
Israel Deaconess Medical Center, Boston, MA.
Despite advances in antiviral therapy, reactivation of latent vari-
cella-zoster virus (VZV) infections remains a signiﬁcant cause of
morbidity following stem cell transplantation (SCT). Twenty-ﬁve
percent or more of patients undergoing SCT will reactivate VZV
in the form of zoster (shingles) within the ﬁrst year after transplant.
Short course (6–12 months) prophylactic therapy with acyclovir
has been shown effective, but compliance with administration up to
5 times daily has been problematic, and outbreaks resumed follow-
ing completion. We undertook a phase III, randomized, double-
blind, placebo-controlled trial of valacyclovir (VACV, 1000 mg
Poster Session II
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twice daily) from 4 months through 2 years following SCT for the
prevention of zoster. VACV is readily converted to acyclovir in
vivo following oral administration, has potent activity against VZV,
and can be dosed twice daily. Fifty-three VZV-seropositive trans-
plant recipients (17 autologous, 36 allogeneic SCT) were random-
ized at a median of 163 days following SCT. Using an intent-to-
treat analysis, the rate of VZV in the VACV arm was 3 of 27 versus
6 of 26 in the placebo arm (P  .21). All three cases in the VACV
arm occurred after randomization but prior to starting VACV.
Using a modiﬁed intent-to-treat analysis comprised of those sub-
jects randomized who took any study drug, 49 subjects started the
planned therapy with VACV or placebo (4 subjects never started: 2
developed zoster and 2 dropped blood counts prior to the time they
were supposed to start; a ﬁfth subject started drug following res-
olution of zoster starting after randomization). The rate of zoster
was 6 of 26 in the placebo arm versus 0 of 23 in the VACV arm
(P  .03). Thirty subjects completed the planned therapy through
the second year after transplant or ﬁrst episode of zoster. Reasons
for discontinuation in the placebo group included adverse reactions
(nausea/vomiting/dehydration in 2 subjects; elevated transami-
nases, low platelets, and joint pains in 1 subject each) and relapse
(4). Reasons in the VACV group included withdrawal of consent
(4), relapse (3), and adverse reactions (1 leukopenia, 1 cramping
abdominal pain). The 6 episodes of zoster were recorded at a
median of 122 days after randomization (278 days after BMT) and
were complicated by 3 episodes of post-herpetic neuralgia. Vala-
cyclovir at a dose of 1000 mg twice daily through the second year
after transplant is well tolerated and effective in preventing the
outbreak of shingles after SCT.
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TREATMENT OF ZYGOMYCOSIS: POSACONAZOLE AS A TREATMENT
OPTION IN 91 CASES
van Burik, J.-A.1, Hare, R.S.2, Solomon, H.F.3, Corrado, M.L.3,
Kontoyiannis, D.P.4 1. University of Minnesota, Minneapolis, MN; 2.
Schering-Plough Research Institute, Kenilworth, NJ; 3. Advanced Bio-
logics LLC, New Hope, PA; 4. University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: Zygomycosis is an emerging opportunistic mycosis
for which few therapies exist and can occur in hematopoietic stem
cell transplant (HSCT) recipients and patients with hematologic
malignancies. We evaluated the use of posaconazole (POS) as
salvage therapy in patients with zygomycosis enrolled in a Scher-
ing-Plough compassionate-use program. Methods: A retrospec-
tive analysis was conducted using questionnaires completed by
investigators treating patients with zygomycosis. Patients were
required to have proven or probable zygomycosis (EORTC/MSG
criteria) and have disease refractory (R) to and/or be intolerant (I)
of prior antifungal therapy. Outcome at 12 weeks was assessed.
Results: The majority (69/91) of patients had proven infection,
and most (48/91) were R or R  I (33/91) to prior therapy. Most
(85%) failed lipid amphotericin B (LAB) therapy, and about half
had 1 month of prior antifungal therapy. Overall success (com-
plete response [CR]  partial response [PR]) was 60% (14% CR,
46% PR). Another 21% of patients had stable disease (SD). Success
by predisposing risk factor (subjects could have had more than 1
risk factor) occurred in 28/48 (60%) patients with hematologic
malignancy, 14/27 (52%) HSCT recipients, and 18/30 (60%) pa-
tients with GVHD. Duration of POS therapy (800 mg/day oral
suspension) ranged from 6 days to nearly 3 years. Success was also
generally similar by site of infection: 23/42 (54%) sinus, 24/37
(65%) pulmonary, 8/13 (62%) cutaneous, 8/11 (73%) brain, and
5/11 (46%) orbital infections. Success was observed for various
species of Zygomycetes. Combination therapy (POS  LAB) for
	10 days in 15 heavily immunosuppressed patients resulted in
similar response (7% CR, 47% PR, 27% SD). Sixty-four patients
(70%) had adjunct surgical debridement (38 patients before POS,
9 patients during POS, 17 patients both before and during POS);
26 patients had no surgery. Thirty-ﬁve patients died while on POS
or within 1 month of follow-up, though only 15 deaths were
considered related to zygomycosis.
Conclusions: Overall success with POS was high, including
patients with hematologic malignancies and HSCT recipients. The
favorable survival rate in this case series provides encouraging data
regarding POS as an alternative to LAB. Further well-controlled
clinical studies are warranted.
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CREATING A CULTURE OF SUPPORT ON A BONE MARROW TRANS-
PLANT UNIT: IT TAKES A VILLAGE
Calderon, K.S.1, Schmid, C.L.1, Partin-Welch, P.H.1, Robinson, N.S.1,
Huber, H.1, Van Loon, R.A.2 1. Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 2. University of Cincinnati, Cincinnati, OH.
The Bone Marrow Transplant Unit at Cincinnati Children’s
Hospital Medical Center (CCHMC) is an 18 bed unit that serves
children from all over the country and internationally for trans-
plants. The usual range of stay in the hospital is about 30–60 days,
but can be much longer. We have found the patients and families
bring not only their medical needs, but many social issues must be
understood and addressed. These include issues related to being
away from home, loss of normal resources, ﬁnancial stress, family
conﬂicts, health and/or behavioral problems of family members,
transportation problems, insurance difﬁculties, and the list contin-
ues. The community of patients and families forms somewhat of a
village. The instant village of the BMT unit requires much atten-
tion and support from a vast array of staff in addition to the medical
team. The needs of the patient and families are as varied and
complicated as are the diseases which brought them to our hospi-
tal. An interdisciplinary and family-centered approach called the
Family Support Network (FSN) has been developed in the Divi-
sion of Hematology and Oncology at CCHMC to address the
needs of the patients and families. The social worker, school
intervention specialist, child life specialist, massage therapist, chap-
lain, and ﬁnancial counselor have become essential personnel to
the transplant process. Every member of the FSN uses a support-
ive, family-centered, and solution-focused approach which be-
comes the new culture for the families. Families are offered support
groups, individual counseling, educational opportunities, and var-
ious self-care interventions (massages, family meals, make-overs,
movies). The patients and families, in turn, utilize services and
begin to support themselves and each other in more adaptive ways.
The acclimation process for patients and families into the culture
begins before they ever come to the hospital, through telephone
contacts and written materials. This process continues in person
during treatment and after-care phases. The FSN staff also pro-
vides support for the nursing and medical team to reduce stress
caused by working with high-acuity patients through de-brieﬁng
sessions, massages, supportive counseling, and educational inter-
ventions (Table 1).
Table 1. Services of the Family Support Network (FSN)
Social Work
School
Intervention Child Life Pastoral Care Financial Service
Emotional
support and
crisis
counseling
Facilitate home
instruction
Creative and
innovative
medical
play
Liaison with
community
clergy
Customer service
for financial
issues
Family support
and diagnosis
onward
Individualized
Education Plans
Sibling
support
Spiritual and
emotional
support
Pre-
authorizations
Resource
connections/
advocacy
School
reintegration
Support and
distraction
Visitation and
prayer
Pre-certifications
Teaching,
education, and
consulting
Pre-school
through college
Therapeutic
play
Reflection Verification of
financial
eligibility
The FSN is committed to helping patients and families through
BMT process.
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